Steve Laflin
Vermögen: 895 069 $ am 31.07.2026
Vermögen: 895 069 $ am 31.07.2026
Steve T.
Laflin is Chief Executive Officer at RadQual LLC since 2021.
Mr. Laflin is Director at Radnostix, Inc. since 2023.
Mr. Laflin was President & Chief Executive Officer at International Isotopes Idaho, Inc. from 1996 to 2001.
Mr. Laflin completed undergraduate studies at Idaho State University.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
RADNOSTIX, INC. 2.42% | 26.05.2026 | 12’786’700 ( 2.42% ) | 895 069 $ | 31.07.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| RADNOSTIX, INC. | Direktor/Vorstandsmitglied | 01.06.2001 |
RadQual LLC
RadQual LLC Medical SpecialtiesHealth Technology Manufactures quality control products for the nuclear medicine and PET imaging communities | Vorstandsvorsitzender | 01.07.2021 |
| Unternehmen | Position | Ende |
|---|---|---|
International Isotopes Idaho, Inc.
International Isotopes Idaho, Inc. Pharmaceuticals: MajorHealth Technology Produces and supplies radioisotopes and brachytherapy for the treatment of cancer | Vorstandsvorsitzender | 01.01.2001 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 4 |
|---|---|
Radnostix, Inc.
Radnostix, Inc. Medical SpecialtiesHealth Technology Manufactures finished radiopharmaceuticals, pharmaceutical grade radiochemical, radioisotopes, brachytherapy medical devices | Health Technology |
Idaho State University
Idaho State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
RadQual LLC
RadQual LLC Medical SpecialtiesHealth Technology Manufactures quality control products for the nuclear medicine and PET imaging communities | Health Technology |
International Isotopes Idaho, Inc.
International Isotopes Idaho, Inc. Pharmaceuticals: MajorHealth Technology Produces and supplies radioisotopes and brachytherapy for the treatment of cancer | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen